^
Association details:
| Biomarker: | Chr t(11;14) |
|---|---|
| Cancer: | Multiple Myeloma |
| Regimen: | VRD (bortezomib + dexamethasone injection + lenalidomide) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy
Published date:
11/01/2018
Excerpt:
Of the 1000 consecutive newly diagnosed myeloma patients treated with RVD induction therapy...Among these patients, we identified 122 patients with t(11;14)....The median progression-free survival for the t(11;14) and non-t(11;14) groups were 51 months (95% confidence interval (CI), 30.628-71.372) and 75 months (95% CI, 57.882-92.118) months, respectively (P<0.001), at a median follow up of 39 months....Even with the use of modern day induction regimens, patients with t(11;14) have inferior outcomes compared to the other patients standard risk myeloma.
